- Record: found
- Abstract: found
- Article: not found
Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
Preprint
Anthonet L. Koen ,
Alane Izu ,
Vicky Baillie ,
Gaurav Kwatra ,
Clare L. Cutland ,
Lee Fairlie ,
Sherman D. Padayachee ,
Keertan Dheda ,
Shaun L. Barnabas ,
Qasim Ebrahim Bhorat ,
Carmen Briner ,
Khatija Ahmed ,
Sutika Bhikha ,
Jinal N. Bhiman ,
Jeanine du Plessis ,
Aliasgar Esmail ,
Elizea Horne ,
Shi-Hsia Hwa ,
Aylin Oommen-Jose ,
Teresa Lambe ,
Matt Laubscher ,
Mookho Malahleha ,
Gabriella Benade ,
Shakeel McKenzie ,
Suzette Oelofse ,
Faeezah Patel ,
Sureshnee Pillay ,
Sarah Rhead ,
Hylton Rodel ,
Carol Taoushanis ,
Houriiyah Tegally ,
Asha Thombrayil ,
Tonya L. Villafana ,
Sarah Gilbert ,
Andrew J. Pollard ,
Shabir A. Madhi
July 18 2022
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-type and 77.1% against the Delta variant ≥9 months after vaccination. VE against infection with the Beta variant, which preceded circulation of Delta, was 6.7%.